CD25/IL2RA Proteins, Antibodies, cDNA Clones Research Reagents

IL2RA (Interleukin 2 Receptor Subunit Alpha, also known as p55; CD25; IL2R; IMD41; TCGFR; IDDM10), located on 10p15.1, is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, and rat. The gene produces a 30819 Da protein composed of 272 amino acids. The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Diseases such as Immunodeficiency 41 With Lymphoproliferation And Autoimmunity and Diabetes Mellitus, Insulin-Dependent, 10 are associated with IL2RA. The related pathways of IL2RA include RET signaling and Signaling by GPCR.

CD25/IL2RA Protein (10)

CD25/IL2RA Antibody (30)

    CD25/IL2RA cDNA Clone (53)

    NM_000417.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_008367.3

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_013163.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    NM_001283704.1

    In expression vector

    NM_001032917.1

    クローニングベクター cDNA 製品

    In lentiviral vector

    CD25/IL2RA Lysate (8)

      CD25/IL2RA の背景知識

      CD25 (alpha-chain of the IL-2 receptor, or IL2RA), is a type I transmembrane glycoprotein with a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. IL2RA is expressed on activated T cells and regulatory T cells and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high-affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covalently with the IL2 receptor beta and gamma chain, and subsequently initiates the intracellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling. The IL2RA (CD25) gene is a substantial component of the high-affinity receptor molecule highly expressed by activated T lymphocytes. Recently, a piece of strong evidence was obtained for the involvement of IL-2RA in conferring susceptibility to type 1 diabetes (T1D). Cancer growth and development are associated with the stimulation of the innate immune system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and its shedding into the circulation in a soluble form of SIL-2Ralpha. In most hematological malignancies, including different types of leukemias and lymphomas, SIL-2Ralpha is released directly from the surface of neoplastic cells thus reflecting the tumor bulk, turnover, and activity. Several studies have proved that not only lymphoid cancer cells but also some non-lymphoid cancer cells, express IL-2R on their surface. They include malignant melanoma and carcinomas of the kidney, head and neck, esophagus, and lung. Thus, sIL-2Ralpha is elevated in most proliferative disturbances of the hematopoietic system and many solid tumors.

      CD25/IL2RA の参考文献

      • Driesen J, et al. (2008) CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology. 213(9-10): 849-58.
      • Olejniczak K, et al. (2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. Med Sci Monit. 14(10): RA179-89.
      • Chistiakov DA, et al. (2008) The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett. 118(1): 1-5.
      • Bien E, et al. (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 13(1): 1-26.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.